Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells

Blood. 2013 Oct 24;122(17):3086-8. doi: 10.1182/blood-2013-04-494773.

Authors

Seiichi Okabe¹, Tetsuzo Tauchi, Yuko Tanaka, Seiichiro Katagiri, Toshihiko Kitahara, Kazuma Ohyashiki

Affiliation

¹ First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.

PMID: 24159169
DOI: 10.1182/blood-2013-04-494773

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology*
Drug Resistance, Neoplasm / drug effects
Fusion Proteins, bcr-abl / antagonists & inhibitors*
Fusion Proteins, bcr-abl / genetics
Fusion Proteins, bcr-abl / metabolism
Gene Expression Regulation, Leukemic
HSP90 Heat-Shock Proteins / antagonists & inhibitors*
HSP90 Heat-Shock Proteins / genetics
HSP90 Heat-Shock Proteins / metabolism
Harringtonines / pharmacology*
Homoharringtonine
Humans
Imidazoles / pharmacology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Primary Cell Culture
Protein Kinase Inhibitors / pharmacology
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
Proto-Oncogene Proteins c-bcl-2 / genetics
Proto-Oncogene Proteins c-bcl-2 / metabolism
Pyridazines / pharmacology
Signal Transduction

Substances

Antineoplastic Agents
HSP90 Heat-Shock Proteins
Harringtonines
Imidazoles
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-bcl-2
Pyridazines
ponatinib
Homoharringtonine
Fusion Proteins, bcr-abl